Lundi 4 juin – 9:24-9:36 – HALL B1
MAPS Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.
V Westeel, G Eberst, A Anota, A. Scherpereel, J. Mazieres, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, H. Léna, F. Rivière, I. Monnet, V. Gounant, H. Janicot, R. Gervais, C. Locher, F. Morin, G. Zalcman
Dimanche 3 juin – 8:00-11:30 – HALL A
Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies
E Auclin, J Taieb, C Lepage, T Aparicio, R Faroux, E Mini, G Folprecht, R Salazar, M Banzi, C Louvet, J-L Van Laethem, J Tabernero, T Hickish, A De Gramont, T Andre, D Vernerey
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.
A F Shields, F-S Ou, J Paul, A F Sobrero, T Yoshino, J Taieb, I Souglakos, Q Shi, R Kerr, R Labianca, T Yamanaka, D Vernerey, I Boukovinas, T Kato, V Torri, S Kakolyris, T Andre, A Grothey, J A Meyerhardt, T Iveson
Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST)
S S Watson, C De La Fouchardiere, S Chong Hun Kim, R Cohen, J-B Bachet, C Tournigand, J-M Ferraz, M Lefevre, D Colin, M Svrcek, A Meurisse, C Louvet
Lundi 4 juin – 1:15-4:45 – HALL A
SENTICOL III: International validation study of sentinel node biopsy in early cervical cancer: A GINECO, ENGOT and GCIG study
F Lecuru, M Mc Cormack, P Hillemans, A Anota, M Leitao, P Mathevet, R Zweemer, K Fujiwara, V Zanagnolo, A G Zahl Eriksson, E Hudson, G Ferron, M Plante
Multicenter randomized controlled trial for advanced cancer patients receiving parenteral nutrition (PN) versus oral feeding (OF): results of AlimK study.
Bouleuc C, Anota A, Cornet C, Grodard G, Thiery-Vuillemin A, Pazart L, Aubry R and the AlimK study Group.
A propos de Sophie PAGET-BAILLY
Sophie Paget-Bailly is a research engineer in epidemiology and clinical research. She passed with honours the East of France inter-region master’s degree in public health and occupational and environmental risks. During the master’s degree’s internship in the Interregional Epidemiology Unit of Bourgogne/Franche-Comté, she realized a quantitative health risk assessment in the context of chemical contamination of groundwater. She defended a PhD in Public Health and Epidemiology in Paris XI University, Doctoral School 420, working in the Centre for Research in Epidemiology and Population Health in Villejuif, France. Her PhD research focused on occupational exposures and head and neck cancer.